SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Bayer CropScience soars on getting NCLT’s nod for merger of Monsanto India with the company

16 Sep 2019 Evaluate

Bayer CropScience is currently trading at Rs. 3271.40, up by 99.25 points or 3.13% from its previous closing of Rs. 3172.15 on the BSE.

The scrip opened at Rs. 3219.05 and has touched a high and low of Rs. 3291.45 and Rs. 3218.00 respectively.

The BSE group 'A' stock of face value Rs. 10 has touched a 52 week high of Rs. 4474.75 on 13-Dec-2018 and a 52 week low of Rs. 2952.00 on 02-Aug-2019.

Last one week high and low of the scrip stood at Rs. 3291.45 and Rs. 3079.30 respectively. The current market cap of the company is Rs. 11223.48 crore.

The promoters holding in the company stood at 68.69%, while Institutions and Non-Institutions held 19.69% and 11.62% respectively.

The National Company Law Tribunal (NCLT) has given an approval for the merger of Monsanto India with Bayer CropScience. In June 2018, German chemical and pharma major Bayer AG had announced completion of the $63 billion mega-deal to acquire US-based biotech major Monsanto to create the world's biggest agro-chemical and seed company.

Bayer had in May received approval from the fair trade regulator Competition Commission of India (CCI), paving way for the completion of the global merger. Bayer CropScience took shareholders' approval for the merger during the first quarter of 2019-20 and was waiting the final approval of the NCLT to make the global merger effective in India.

Bayer CropScience is engaged in the manufacturing of crop protection products like herbicides, insecticides, fungicides and seed treatment, non agricultural pest-control, seeds and plant biotechnology.

Bayer CropScience Share Price

4900.45 -32.85 (-0.67%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
UPL 665.00
PI Industries 3144.45
Bayer CropScience 4900.45
Sharda Cropchem 1109.70
Sumitomo Chemical 441.95
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×